NVS (Novartis) received full FDA approval for Fabhalta for IgA nephropathy after Phase III data showed a slower decline in kidney function. The approval strengthens its nephrology portfolio and is a meaningful positive regulatory milestone for the drug’s commercial outlook.
NVS (Novartis) received full FDA approval for Fabhalta for IgA nephropathy after Phase III data showed a slower decline in kidney function. The approval strengthens its nephrology portfolio and is a meaningful positive regulatory milestone for the drug’s commercial outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
